FWDIHIGH SIGNALFINANCIAL10-K

FWDI underwent a massive share count increase from 1.1M to 86.5M shares outstanding while experiencing substantial revenue decline and significant balance sheet deleveraging.

The dramatic share dilution suggests a major corporate restructuring, stock split, or financing event that fundamentally altered the company's capital structure. Combined with meaningful revenue contraction and substantial debt reduction, this indicates FWDI is navigating a significant transformation that materially impacts shareholder economics and business scale.

Comparing 2025-12-11 vs 2024-12-27View on EDGAR →
FINANCIAL ANALYSIS

The company's financial profile contracted meaningfully with revenue declining substantially to $18.2M while gross profit showed more resilience, falling modestly to $5.2M. Balance sheet changes were pronounced, with current liabilities and total liabilities declining significantly alongside a major reduction in accounts receivable, suggesting either business downsizing or collection of outstanding receivables. The combination of reduced capital expenditure and stable cash position indicates a more conservative operational stance during this period of transition.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
-70.9%
$9.4M$2.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Accounts Receivable
Balance Sheet
-70.8%
$5.6M$1.6M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Capital Expenditure
Cash Flow
-60.4%
$65K$26K

Capex reduced 60.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Liabilities
Balance Sheet
-59.2%
$11.8M$4.8M

Liabilities reduced 59.2% — deleveraging improves balance sheet strength and financial flexibility.

Inventory
Balance Sheet
+46.5%
$334K$490K

Inventory surged 46.5% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

Revenue
P&L
-39.8%
$30.2M$18.2M

Revenue declined 39.8% — significant demand weakness or market share loss warrants investigation.

Interest Expense
P&L
-21.6%
$63K$49K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Cash & Equivalents
Balance Sheet
+17.8%
$4.0M$4.8M

Cash grew 17.8% — improving liquidity position supports investment and shareholder returns.

Gross Profit
P&L
-16.4%
$6.2M$5.2M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

LANGUAGE CHANGES
NEW — 2025-12-11
PRIOR — 2024-12-27
ADDED
There were 86,459,465 shares of the registrant s common stock outstanding as of December 5, 2025.
Market for Registrant's Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities 31 Item 6.
Management's Discussion and Analysis of Financial Condition and Results of Operations 31 Item 7A.
( Forward US ), DE Sub 1, LLC ( Forward Delaware ), Forward Industries (Switzerland) GmbH ( Forward Switzerland ), Forward Industries UK Limited ( Forward UK ), Intelligent Product Solutions, Inc.
( Kablooe ), is a design company serving top tier medical and technology customers.
+7 more — sign up free →
REMOVED
There were 1,101,069 shares of the registrant s common stock outstanding as of December 6, 2024.
Market for Registrant s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities 18 Item 6.
Management s Discussion and Analysis of Financial Condition and Results of Operations 18 Item 7A.
( Forward US ), Forward Industries (Switzerland) GmbH ( Forward Switzerland ), Forward Industries UK Limited ( Forward UK ), Intelligent Product Solutions, Inc.
( Kablooe ), is a global design, sourcing and distribution company serving top tier medical and technology customers worldwide.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →